FTC Release: FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)--Caremark Rx, Express Scripts (ESI), and OptumRx--and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,